Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle & NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion & Other Forms of Traumatic Brain Injury.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"NorthShore University HealthSystem"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Odyssey Health"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in AVITA Medical\u2019s Pivotal Study Evaluating RECELL\u00ae System for Pediatric Scald Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Avita Medical"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Neuronasal"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Files Patent for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Annovis Bio"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panaxia's Agreement with International Pharma Neuraxpharm is Finalized","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Neuraxpharm"},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Exalys Therapeutics"},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming\u00ae System","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Safi Biosolutions"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Chrysalis BioTherapeutics"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Statera Biopharma"},{"orgOrder":0,"company":"MiMedx","sponsor":"U.S. Army Medical Research and Development","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"MiMedx"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$9.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Cerus Corporation"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL\u00ae System for Soft Tissue Repair","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Avita Medical"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Defence R&D Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Revive Therapeutics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Revive Therapeutics"}]

Find Novel Drugs for Trauma (Emergency, Injury, Surgery) under Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.

            Lead Product(s): Bucillamine,Acetylcysteine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims to evaluate Bucillamine, a significantly more effective antioxidant than n-acetylcysteine, as a potential treatment for nerve agent exposure.

            Lead Product(s): Bucillamine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Defence R&D Canada

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells.

            Lead Product(s): Regenerative Epidermal Cell

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RECELL

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic injury bleeding.

            Lead Product(s): Pathogen Reduced Lyophilized Cryoprecipitate

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LyoCryo

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $9.1 million Upfront Cash: Undisclosed

            Deal Type: Funding November 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The award will be used to advance the clinical understanding of PURION® processed Dehydrated Human Amnion Chorion Membrane, specifically in treating acute injuries and preventing initially partial-thickness burns from deteriorating to full-thickness burns.

            Lead Product(s): Dehydrated Human Amnion Chorion Membrane

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: DHACM

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: U.S. Army Medical Research and Development

            Deal Size: $4.6 million Upfront Cash: Undisclosed

            Deal Type: Funding May 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Statera is establishing a development program in Oncology and Hematology based on the potential that toll-like receptor 5 agonists, such as Entolimod, have shown in the treatment of neutropenia and anemia in cancer patients.

            Lead Product(s): Entolimod

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STAT-600

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Chrysalis will conduct safety studies and additional options required to achieve Emergency Use Authorization and Animal Rule approval for TP508 as a medicinal treatment for acute and delayed effects of ionizing radiation exposure.

            Lead Product(s): Rusalatide Acetate

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TP508

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $10.4 million Upfront Cash: Undisclosed

            Deal Type: Funding December 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            iBio will manufacture 10 proteins to be tested in the production of Safi’s cell therapies as part of the first Statement of Work. Safi will have the option to designate certain proteins as proprietary to their bioprocess, but iBio will have rights to market all other products.

            Lead Product(s): Blood cell therapy

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: iBio

            Deal Size: $1.5 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.

            Lead Product(s): Cannabis products

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Panaxia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.

            Lead Product(s): Undisclosed

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Catalys Pacific

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY